Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-NIVO Combined With Sacituzumab Govitecan for Cisplatin-ineligible Metastatic Urothelial Carcinoma
NCT04863885Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in urothelial carcinoma (UC), sponsored by Moffitt Cancer Center. Started Apr 2021; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04863885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863885.